Why the study?
Does elevated sST2 improve cardiovascular risk prediction compared to cTnT in kidney transplant candidates?
Population
200 kidney transplant candidates between 2010 and 2013, median age 53 years, 59.7% male, 82.0% white.
Comparison
Elevated sST2 (≥30ng/ml) vs Elevated cTnT (≥0.01 ng/ml)
Design
Cohort
Follow-up
28 months (IQR 25.3-30)
Authors
Loading...
sST2 adds no incremental prognostic value over cTnT in transplant candidates; leaves open its role in broader CKD risk stratification.
Does elevated sST2 improve cardiovascular risk prediction compared to cTnT in kidney transplant candidates?
In kidney transplant candidates, sST2 does not provide independent prognostic value over cardiac troponin T for predicting cardiovascular events and mortality.
Keddis et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: